Abstract: The present invention relates to a method of screening for a cancer therapeutic agent using Cyclin B1, Cyclin-dependent kinase 1 (CDK1), and retinoic acid receptor responder 1 (RARRES1), and a composition for diagnosing cancer or predicting a prognosis using the same. As a result of having conducted intensive studies to discover molecular mechanisms for diagnosing cancer and predicting a prognosis, the inventors of the present invention confirmed that in cancer-derived samples, according to the degree of mutual binding between RARRES1 and CDK1 or Cyclin B1, the mitosis of cancer cells was arrested, the formation of CDK1-Cyclin B1 complexes was suppressed, and the degradation of these proteins was promoted, and thus RARRES1 was a crucial factor in the diagnosis of cancer, prognosis prediction, and the treatment of cancer.

Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.

Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.

Abstract: The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising: (1) analyzing a methylation level of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene in a sample taken from a human subject; and (2) predicting the effect of the medicinal therapy on the cancer based on the analyzed methylation level.

Abstract: The present invention relates to an antibody-fluorescent dye conjugate capable of cancer cell-specific fluorescence imaging diagnosis. The fluorescent dye comprises a covalently labeled antibody and is quenched by interaction with an amino acid residue such as tryptophan, tyrosine, histidine, and methionine in the antibody and upon binding of the antibody to an antigen present on a cell surface to emit fluorescence, whereby cells having a target antigen thereon can be imaged for diagnosis. When using the antibody-fluorescent dye conjugate according to the present invention during in vitro cell assays, high-throughput screening of cells, and cytodiagnosis based on microfluidics, the presence of cancer cells having a specific antigen expressed thereon can be detected at high specificity and sensitivity without a washing process, and the position of primary and metastatic cancer cells can be detected at high contrast within a short time.

Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.

Abstract: [Problem] The present invention provides an antibody that binds to TMEM132A, an anticancer agent and a cancer test method. [Solution] An antibody that binds to TMEM132A.

Abstract: The present invention provides a method for acquiring data relating to the onset of cerebral infarction, characterized in that the method includes determining the level of an antibody to DIDO1 protein or a portion thereof, and/or the level of an antibody to CPSF2 protein or a portion thereof, the antibody or antibodies being present in a body fluid sample collected from a living body. The invention also provides a kit for acquiring data for carrying out the method of the present invention. The invention can accurately discern signs linked to the onset of cerebral infarction.

Abstract: The present invention provides an alginic acid-based injectable hydrogel system for labeling an accurate position of a disease lesion and effectively delivering a drug to a target region. The formulation of the present invention can make it easy to locally inject a contrast agent and a drug into a target region while controlling the release rate of the contrast agent or the drug, with the formation of the hydrogel in the injected region. Through the advantages, the labeled position can be accurately determined from images, thereby enhancing the precision of surgical operation, with a minimal incision formed therefor. In addition, when used, the alginic acid-based injectable hydrogel system allows the effective local delivery of a drug to a target region while increasing the long-acting effect of the drug.

Abstract: An annotation support apparatus manages a medical image on the basis of an attribute of each medical image, using a hierarchical structure that has one medical image as a node and includes a medical image hierarchy to which a node of the medical image belongs and at least one of an upper hierarchy higher than the medical image hierarchy or a lower hierarchy lower than the medical image hierarchy. The annotation support apparatus includes: an image acquisition unit that acquires the medical image; a display unit; an annotation input receiving unit that receives designation of any one of the node of the medical image or a node associated with the node of the medical image in the hierarchical structure and an input of annotation information related to the designated node; and an annotation storage unit that stores the annotation information to be associated with the designated node.

Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.

Abstract: Provided is a method for treating or preventing cancer, containing, as an active ingredient, a compound having a specific chemical structure and an activity of inhibiting the formation of a c-Myc/Max/DNA complex, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.

Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.

Abstract: The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agents capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.

Abstract: An indicator may have improved accuracy for predicting an effect of a medicinal therapy on breast cancer. The method may estimate a breast cancer cell existence ratio and other methods, the method including: (1) analyzing methylation level of (1a) a cytosine residue in a CG portion of nucleotides at positions 1,000 to 1,001 in a nucleotide sequence of SEQ ID NO: 1, (1b) a cytosine residue in a CG portion of nucleotides at positions 1,000 to 1,001 in a nucleotide sequence of SEQ ID NO: 2, (1c) a cytosine residue in a CG portion of nucleotides at positions 1,001 to 1,002 in a nucleotide sequence of SEQ ID NO: 3, or (1d) a combination of the cytosine residues, in a sample derived from a human subject; and (2) estimating the breast cancer cell existence ratio in the sample, based on the methylation level analyzed at (1).

Abstract: A method includes: inputting an image of a target to each of a first model for estimating a region of an annular face of the target, a second model for estimating a region in an outer circumference of the annular face and a third model for estimating a region in an inner circumference of the annular face, and outputting a region image, as an estimated region of the annular face, the region image being obtained by synthesizing first, second, and third elements. The first element is a region outputted as a result of the first model for calculating a sum set in the synthesizing, the second element is a region outputted as a result of the second model for calculating a sum set in the synthesizing, and the third element is a region outputted as a result of the third model for calculating a difference set in the synthesizing.

Abstract: A method includes: acquiring data including moving image obtained by photographing a target and annotation images each indicative of a region of the target in each of frame images in the moving image; executing a process using the data. The process includes: detecting the target in the frame images; inputting, to an auto-encoder, an image obtained by combining partial images including the target and peripheral region images of the target detected in a given number of preceding and succeeding second frame images in a time series of the moving image of a first frame image; inputting a partial image corresponding to the first frame image to a neural network performing a segmentation; updating parameter of the auto-encoder and the neural network based on a difference between an image obtained by combining images from the auto-encoder and the neural network and a partial image of the annotation image.

Abstract: A method includes: acquiring a training data set including pieces of training data, each of the pieces including an image of a training target, first annotation data representing a rectangular region in the image, and second annotation data; training, based on the image and the first annotation data, an object detection model specifying a rectangular region including the training target; training, based on the image and the second annotation data, a neural network; and calculating a first index value related to a relationship of a pixel number, the trained estimation model and the calculated first index value being used in a determination process that determines, based on the calculated first index value and a second index value relationship between a pixel number in an output result and an estimation result, whether or not a target in a target image is normal.

Abstract: This application provides a kit or a device for detection of ovarian tumor, comprising a nucleic acid(s) for detecting a miRNA(s) in a sample from a subject, and a method for detecting ovarian tumor, comprising measuring the miRNA(s) in vitro.